EP1836313A4 - METHOD OF ESTIMATING PATIENTS SUFFERING FROM ACUTE MYELOID LEUKEMIA - Google Patents

METHOD OF ESTIMATING PATIENTS SUFFERING FROM ACUTE MYELOID LEUKEMIA

Info

Publication number
EP1836313A4
EP1836313A4 EP05854761A EP05854761A EP1836313A4 EP 1836313 A4 EP1836313 A4 EP 1836313A4 EP 05854761 A EP05854761 A EP 05854761A EP 05854761 A EP05854761 A EP 05854761A EP 1836313 A4 EP1836313 A4 EP 1836313A4
Authority
EP
European Patent Office
Prior art keywords
estimating
myeloid leukemia
patients suffering
acute myeloid
acute
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05854761A
Other languages
German (de)
French (fr)
Other versions
EP1836313A2 (en
Inventor
Mitch Raponi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Diagnostics LLC
Original Assignee
Veridex LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veridex LLC filed Critical Veridex LLC
Publication of EP1836313A2 publication Critical patent/EP1836313A2/en
Publication of EP1836313A4 publication Critical patent/EP1836313A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/50—Detection characterised by immobilisation to a surface
    • C12Q2565/501—Detection characterised by immobilisation to a surface being an array of oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP05854761A 2004-12-17 2005-12-19 METHOD OF ESTIMATING PATIENTS SUFFERING FROM ACUTE MYELOID LEUKEMIA Withdrawn EP1836313A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63726504P 2004-12-17 2004-12-17
US67011605P 2005-04-11 2005-04-11
US74118005P 2005-12-01 2005-12-01
PCT/US2005/046100 WO2006066240A2 (en) 2004-12-17 2005-12-19 Methods for assessing patients with acute myeloid leukemia

Publications (2)

Publication Number Publication Date
EP1836313A2 EP1836313A2 (en) 2007-09-26
EP1836313A4 true EP1836313A4 (en) 2010-06-30

Family

ID=36588648

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05854761A Withdrawn EP1836313A4 (en) 2004-12-17 2005-12-19 METHOD OF ESTIMATING PATIENTS SUFFERING FROM ACUTE MYELOID LEUKEMIA

Country Status (9)

Country Link
EP (1) EP1836313A4 (en)
JP (1) JP2008523822A (en)
KR (1) KR20070099564A (en)
AU (1) AU2005316291A1 (en)
BR (1) BRPI0515794A (en)
CA (1) CA2589055A1 (en)
IL (1) IL183555A0 (en)
MX (1) MX2007007401A (en)
WO (1) WO2006066240A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100617467B1 (en) * 2005-09-27 2006-09-01 디지탈 지노믹스(주) Prediction Markers for Anticancer Drug Response in Patients with Acute Myeloid Leukemia
JP2010516291A (en) * 2007-01-31 2010-05-20 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション MicroRNA-based methods and compositions for diagnosis, prognosis and treatment of acute myeloid leukemia (AML)
EP2056110A1 (en) * 2007-10-31 2009-05-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Biomarker for the prediction of responsiveness to an anti-tumour necrosis factor alpha (TNF) treatment
JP2011520183A (en) * 2008-04-25 2011-07-14 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ Classification of sample data
US7736861B1 (en) * 2009-10-19 2010-06-15 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
WO2011131246A1 (en) * 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
WO2012007783A1 (en) * 2010-07-13 2012-01-19 Institut Gustave Roussy Kits and methods for detecting the ability to induce an immunogenic cancer cell death in a subject
CA3081061C (en) 2010-07-27 2023-01-03 Genomic Health, Inc. Method for using expression of klk2 to determine prognosis of prostate cancer
KR101660322B1 (en) * 2011-04-28 2016-09-29 아크레이 가부시키가이샤 Probe for detecting mutation in exon12 of npm1 gene and use thereof
KR101922761B1 (en) * 2015-11-18 2018-11-27 가톨릭대학교 산학협력단 A Real-time Quantitative PCR Analysis for the c-Kit mutant detection to Diagnose an Acute Myeloid Leukaemia and the Use thereof
CN116004819B (en) * 2022-08-19 2025-10-31 安徽同科生物科技有限公司 AML-related lncRNA markers, detection kit and application of method in AML diagnosis and prognosis

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"Affymetrix GeneChip Human Genome U133 Array Set HG-U133A", GEO,, 11 March 2002 (2002-03-11), XP002254749 *
BULLINGER L ET AL: "USE OF GENE-EXPRESSION PROFILING TO IDENTIFY PROGNOSTIC SUBCLASSES IN ADULT ACUTE MYELOID LEUKEMIA", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US LNKD- DOI:10.1056/NEJMOA031046, vol. 350, no. 16, 15 April 2004 (2004-04-15), pages 1605 - 1616, XP009059431, ISSN: 1533-4406 *
GREENBAUM DOV ET AL: "Interrelating different types of genomic data, from proteome to secretome: 'Oming in on function", GENOME RESEARCH, COLD SPRING HARBOR LABORATORY PRESS, WOODBURY, NY, US, vol. 11, no. 9, 1 September 2001 (2001-09-01), pages 1463 - 1468, XP009088703, ISSN: 1088-9051, DOI: 10.1101/GR.207401 *
KOHLMANN A ET AL: "GENE EXPRESSION PROFILES OF DISTINCT AML SUBTYPES IN COMPARISON TO NORMAL BONE MARROW", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 98, no. 11, PART 01, 16 November 2001 (2001-11-16), XP001108980, ISSN: 0006-4971 *
RAPONI MITCH ET AL: "IDENTIFICATION OF MOLECULAR PREDICTORS OF RESPONSE TO ZARNESTRA (TM) (TIPIFARNIB, R115777) IN RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 104, no. 11, PART 1, 1 November 2004 (2004-11-01), XP009072584, ISSN: 0006-4971 *
SCHOCH CLAUDIA ET AL: "Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US LNKD- DOI:10.1073/PNAS.142103599, vol. 99, no. 15, 23 July 2002 (2002-07-23), pages 10008 - 10013, XP002215484, ISSN: 0027-8424 *
VALK P J M ET AL: "PROGNOSTICALLY USEFUL GENE-EXPRESSION PROFILES IN ACUTE/MYELOID LEUKEMIA", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US LNKD- DOI:10.1056/NEJMOA040465, vol. 350, no. 16, 15 April 2004 (2004-04-15), pages 1617 - 1628, XP009060381, ISSN: 1533-4406 *

Also Published As

Publication number Publication date
MX2007007401A (en) 2007-10-08
EP1836313A2 (en) 2007-09-26
JP2008523822A (en) 2008-07-10
IL183555A0 (en) 2007-09-20
WO2006066240A2 (en) 2006-06-22
AU2005316291A1 (en) 2006-06-22
WO2006066240A8 (en) 2006-09-08
BRPI0515794A (en) 2008-08-05
WO2006066240A3 (en) 2008-07-17
KR20070099564A (en) 2007-10-09
CA2589055A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
FR2916839B1 (en) METHOD OF ESTIMATING THE PRECISION OF AZIMUTAL ORIENTATIONS
FR2861180B1 (en) METHOD FOR ESTIMATING THE CHARACTERISTICS OF PRECIPITATION
EP1589681A4 (en) APPARATUS FOR ESTIMATING FREQUENCY OF FAILURE
FR2917520B1 (en) METHOD OF ESTIMATING CORROSION
EP1905195A4 (en) ESTIMATION OF DSL SYSTEM
EP1696877A4 (en) METHODS FOR TREATING PAIN
BRPI0311233A2 (en) diagnosis of hepatocellular carcinoma
FR2881732B1 (en) PROCESS FOR THE PURIFICATION OF HYDROGEN CHLORIDE
FR2858063B1 (en) METHOD FOR ESTIMATING THE ILLUMINATION COVERAGE RATE IN THE MIGRE DOMAIN
HUE036677T2 (en) Methods for Multiple Sclerosis Treatment
DE60218451D1 (en) 15-KETO-PROSTAGLANDINE FOR THE TREATMENT OF DRUG-INDUCED OBSTIPATION
EP1886622A4 (en) APPARATUS FOR ESTIMATING THE STERILIZATION OF AN ENDOSCOPE
EP1740923A4 (en) HYSTERESE COMPENSATION METHOD
FI20030778A0 (en) Determination or prediction of disease
EP1883351A4 (en) METHOD FOR PREDICTING THE GLYCEMIC RATE OF A PERSON
EP1743953A4 (en) PROCESS FOR FORMING COPPER FILM
EP1974369A4 (en) METHOD FOR MICROMINIATURIZATION OF NANOSTRUCTURE
EP1624603A4 (en) WAY ESTIMATING CIRCUIT AND WAY ESTIMATING METHOD
EP1676578A4 (en) METHOD FOR STABILIZING DIARYLVINYLENE COMPOUND
EP1752761A4 (en) METHOD FOR MEASURING THE CONCENTRATION OF AN IMPURITY ELEMENT
EP1718631A4 (en) CYTOTOXIN COMPOUND AND METHOD OF ISOLATION
EP1825611A4 (en) CHANNEL ESTIMATING METHOD BASED ON DIVERSITY OF PILOTS
EP1784216A4 (en) S100 PROTEIN INHIBITORS FOR THE TREATMENT OF LEUKEMIA
EP1770067A4 (en) METHOD OF ESTIMATING THE TREND TO AGGLOMERATE FROM A CRYSTALLINE SODIUM HYDROGENOCARBONATE CRYSTALLINE GRAIN
EP1658307A4 (en) METHODS FOR PREVIOUS DIAGNOSIS OF OVARIAN CANCER

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070711

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1107710

Country of ref document: HK

R17D Deferred search report published (corrected)

Effective date: 20080717

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/68 20060101ALI20080827BHEP

Ipc: C12P 19/34 20060101ALI20080827BHEP

Ipc: C07H 21/04 20060101ALI20080827BHEP

Ipc: C07H 21/02 20060101AFI20080827BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100602

17Q First examination report despatched

Effective date: 20110401

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110812

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1107710

Country of ref document: HK